Amicus Therapeutics, Inc. (FOLD) Position Raised by GW&K Investment Management LLC

GW&K Investment Management LLC raised its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 8.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 297,349 shares of the biopharmaceutical company’s stock after buying an additional 22,289 shares during the period. GW&K Investment Management LLC’s holdings in Amicus Therapeutics were worth $4,279,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the business. FMR LLC increased its holdings in Amicus Therapeutics by 3.4% in the second quarter. FMR LLC now owns 21,437,508 shares of the biopharmaceutical company’s stock valued at $215,876,000 after buying an additional 705,153 shares in the last quarter. Perceptive Advisors LLC increased its holdings in Amicus Therapeutics by 3.4% in the third quarter. Perceptive Advisors LLC now owns 17,888,597 shares of the biopharmaceutical company’s stock valued at $269,760,000 after buying an additional 591,925 shares in the last quarter. Redmile Group LLC increased its holdings in Amicus Therapeutics by 5.9% in the second quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after buying an additional 668,080 shares in the last quarter. Jennison Associates LLC increased its holdings in Amicus Therapeutics by 9.4% in the third quarter. Jennison Associates LLC now owns 9,772,025 shares of the biopharmaceutical company’s stock valued at $147,362,000 after buying an additional 838,267 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Amicus Therapeutics by 5.0% in the second quarter. Vanguard Group Inc. now owns 9,118,246 shares of the biopharmaceutical company’s stock valued at $91,821,000 after buying an additional 430,486 shares in the last quarter.

A number of brokerages have issued reports on FOLD. Chardan Capital reaffirmed a “buy” rating and issued a $18.50 target price (up from $16.50) on shares of Amicus Therapeutics in a report on Thursday, October 5th. Robert W. Baird reaffirmed an “outperform” rating and issued a $18.00 target price (up from $16.00) on shares of Amicus Therapeutics in a report on Wednesday, October 4th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Amicus Therapeutics in a report on Wednesday, October 4th. Goldman Sachs Group reissued a “neutral” rating and set a $17.00 price objective on shares of Amicus Therapeutics in a research note on Friday, October 6th. Finally, BidaskClub raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, January 15th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Amicus Therapeutics has a consensus rating of “Buy” and an average price target of $18.31.

In other Amicus Therapeutics news, CEO John F. Crowley sold 65,581 shares of Amicus Therapeutics stock in a transaction that occurred on Thursday, December 21st. The shares were sold at an average price of $13.51, for a total value of $885,999.31. Following the completion of the sale, the chief executive officer now directly owns 393,076 shares of the company’s stock, valued at approximately $5,310,456.76. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Jay Barth sold 5,000 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $14.71, for a total transaction of $73,550.00. Following the completion of the sale, the insider now directly owns 69,184 shares of the company’s stock, valued at $1,017,696.64. The disclosure for this sale can be found here. Insiders sold a total of 197,890 shares of company stock valued at $2,767,181 over the last ninety days. 3.40% of the stock is owned by corporate insiders.

Amicus Therapeutics, Inc. (NASDAQ:FOLD) opened at $15.97 on Tuesday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.22 and a current ratio of 6.32. Amicus Therapeutics, Inc. has a 12 month low of $5.07 and a 12 month high of $16.60. The firm has a market cap of $2,643.68, a P/E ratio of -8.73 and a beta of 1.72.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.10). Amicus Therapeutics had a negative return on equity of 63.54% and a negative net margin of 1,092.37%. The business had revenue of $10.90 million for the quarter, compared to analysts’ expectations of $9.02 million. During the same period last year, the business earned ($0.33) earnings per share. The company’s revenue for the quarter was up 419.0% on a year-over-year basis. research analysts predict that Amicus Therapeutics, Inc. will post -1.52 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece was published by BBNS and is the sole property of of BBNS. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://baseballnewssource.com/markets/amicus-therapeutics-inc-fold-position-raised-by-gwk-investment-management-llc/1859166.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).

Institutional Ownership by Quarter for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped


Leave a Reply

 
© 2006-2018 BBNS.